Back to News
Market Impact: 0.25
Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
Source: Nasdaq
Corporate EarningsCompany Fundamentals
Bristol Myers Squibb’s Growth Portfolio of newer drugs rose 12% to $7.7 billion in the third quarter, supplying nearly all of the company’s 7% revenue increase to $13.1 billion.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Norwegian shares surge 13% on earnings beat, guidance raise
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates